34 results match your criteria: "Patras University General Hospital[Affiliation]"
Int J Impot Res
December 2014
Department of Internal Medicine, Patras University General Hospital, Rio (Patras), Greece.
Crit Rev Microbiol
September 2016
a Department of Internal Medicine & Infectious Diseases , Patras University General Hospital, Patras , Greece.
HIV-1 entry begins with viral envelope glycoprotein gp120 interacting with host-cell CD4 and an entry coreceptor (mainly chemokine receptors CCR5 or CXCR4). Inhibitors of particular coreceptors are being developed in order to exploit this step of cellular infection. However, effectiveness of these drugs requires matching of the administered therapeutic to coreceptor use by the viral variants infecting each patient.
View Article and Find Full Text PDFInt J Infect Dis
December 2013
Division of Infectious Diseases, Department of Internal Medicine, Patras University General Hospital, Patras, Greece; Department of Microbiology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, 54006, Greece.
Background: The Crimean-Congo hemorrhagic fever virus (CCHFV) presents a wide distribution, with the Balkan Peninsula being among the endemic regions. To date, only one CCHF case has been reported in Greece; however, based on seroprevalence data, there is evidence that CCHFV circulates in the country. Achaia is a prefecture in western Greece that has not previously been studied for CCHFV.
View Article and Find Full Text PDFCrit Rev Microbiol
August 2014
Division of Infectious Diseases, Department of Internal Medicine, Patras University General Hospital, Patras , Greece .
Hantaviruses comprise an emerging global threat for public health, affecting about 30,000 humans annually. Infection may lead to Hantavirus pulmonary syndrome (HPS) in the Americas and hemorrhagic fever with renal syndrome (HFRS) in the Europe and Asia. Humans are spillover hosts, acquiring infection primarily through the inhalation of aerosolized excreta from infected rodents and insectivores.
View Article and Find Full Text PDFAntimicrob Agents Chemother
December 2012
Department of Internal Medicine, Patras University General Hospital, Greece.
We report the first case of cefepime-induced "red-man syndrome," which appeared 30 min following drug infusion and was confirmed with a rechallenge test. This syndrome is classically associated with vancomycin infusion and is the result of non-IgE mediated mast cell degranulation. While this adverse effect can be easily managed with drug withdrawal and antihistamine administration, it is unknown whether it can be prevented with slower cefepime infusion and preinfusion antihistamines, as is the case with vancomycin.
View Article and Find Full Text PDFCrit Rev Microbiol
November 2012
Division of Infectious Diseases, Department of Internal Medicine, Patras University General Hospital, Patras, Greece.
Hantaviruses cause Hantavirus Pulmonary Syndrome (HPS; also called Hantavirus Cardiopulmonary Syndrome) in the Americas and Hemorrhagic Fever with Renal Syndrome (HFRS) in Asia and Europe. In Scandinavia and northern Europe, a milder form of HFRS is prevalent, termed nephropathica epidemica (NE). HPS presents with acute respiratory failure, mild-moderate renal failure, thrombocytopenia, and reactive lymphocytosis.
View Article and Find Full Text PDFJ Clin Virol
May 2012
Department of Infectious Diseases, Patras University General Hospital, Greece.
Expert Opin Pharmacother
March 2011
University of Patras, Patras University General Hospital, Urology, Patras, Greece.
Introduction: Locally advanced or metastatic renal cell carcinoma (RCC) is notoriously chemo- and radioresistant, leaving immunotherapy as the only treatment option. In recent years, targeted therapies have offered significant increases in progression-free survival (PFS). Despite this, the majority of patients soon develops resistant disease and finally succumbs.
View Article and Find Full Text PDFExpert Opin Ther Pat
February 2009
Urology Department, Urology Patras University General Hospital, Rion, Patras, Greece.
Background: Overactive bladder is a prevalent and bothersome condition. Existing pharmacotherapy with antimuscarinics improves symptoms and quality of life but there are certain limitations in efficacy and tolerability.
Objective: To review novel, recently patented compounds for the treatment of overactive bladder.